Research Topics
| Jonathan MeyerSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 yearJonathan M Meyer
Department of Psychiatry, University of California, San Diego, USA
J Clin Psychiatry 63:425-33. 2002..The goal of this retrospective study was to examine the changes in weight parameters, fasting glucose, and fasting lipids in long-term inpatients treated with either risperidone or olanzapine...- Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer
Department of Psychiatry, University of California at San Diego, USA
Biol Psychiatry 66:1013-22. 2009..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment... - Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Jonathan M Meyer
Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
Schizophr Res 103:104-9. 2008..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial... - The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer
VA San Diego Healthcare System, USA
Schizophr Res 80:9-18. 2005.... - Antipsychotic safety and efficacy concernsJonathan M Meyer
Department of Psychiatry, University of California, San Diego, CA 92161, USA
J Clin Psychiatry 68:20-6. 2007..Given the widespread use of atypical antipsychotics, the psychiatric community has come to recognize that monitoring of metabolic side effects is the new standard of care for treating severely mentally ill patients... - Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Jonathan M Meyer
Department of Psychiatry, University of California, San Diego, USA
Schizophr Res 101:273-86. 2008..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial... - Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trialJonathan M Meyer
Department of Psychiatry, University of California, San Diego 92161, USA
J Clin Psychiatry 68:28-33. 2007..Mental health providers in the United States are now studying models that support the integration of psychiatric and nonpsychiatric medical treatment to address the complexity of multimodal schizophrenia care... - Prevalence of the metabolic syndrome in veterans with schizophreniaJonathan Meyer
Veterans Affairs San Diego Healthcare System and University of California, San Diego School of Medicine, USA
J Psychiatr Pract 12:5-10. 2006..S. veterans with schizophrenia... - Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label studyJonathan M Meyer
Veterans Administration San Diego Healthcare System, California 92161, USA
Clin Ther 27:1930-41. 2005.... - Lithium toxicity after switch from fosinopril to lisinoprilJonathan M Meyer
Department of Psychiatry, Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA 92161, USA
Int Clin Psychopharmacol 20:115-8. 2005.... - The metabolic syndrome and schizophreniaJ M Meyer
Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA
Acta Psychiatr Scand 119:4-14. 2009.... - Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot studyJonathan M Meyer
University of California, San Diego and San Diego VAMC, 92161, USA
Ann Clin Psychiatry 14:39-45. 2002..These findings have significant implications for programmatic measures to control weight gain among chronic inpatients, and for use of atypicals that have a greater propensity to cause weight gain... - Antipsychotics and metabolics in the post-CATIE eraJonathan M Meyer
Department of Psychiatry, University of California, La Jolla, CA 92093, USA
Curr Top Behav Neurosci 4:23-42. 2010.... - Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State HospitalJonathan M Meyer
University of California, San Diego, USA
J Clin Psychiatry 64:540-5. 2003..S. psychiatric patients without mental retardation who are HCV-seropositive. To address this issue, a comprehensive screening program was commenced at Oregon State Hospital (Salem, Ore.) beginning in 1999... - Lurasidone: a new drug in development for schizophreniaJonathan M Meyer
Department of Psychiatry, University of California, San Diego, CA 92161, USA
Expert Opin Investig Drugs 18:1715-26. 2009..Lurasidone is a novel psychotropic agent in development for the treatment of schizophrenia and bipolar disorder... - Quetiapine-induced diabetes with metabolic acidosisJonathan M Meyer
Department of Psychiatry, Veterans Affairs San Diego Healthcare System, San Diego, California, USA
Int Clin Psychopharmacol 19:169-71. 2004..This case illustrates another mechanism for sexual adverse effects, and the need for routine inquiry into sexual dysfunction during atypical antipsychotic therapy... - The effects of antipsychotic therapy on serum lipids: a comprehensive reviewJonathan M Meyer
University of California, San Diego VAMC MC 116A, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
Schizophr Res 70:1-17. 2004.... - The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophreniaJonathan M Meyer
Department of Psychiatry, VA San Diego Healthcare System and University of California, San Diego, CA, USA
J Clin Psychiatry 70:318-25. 2009..Race is strongly associated with risk for metabolic dysfunction, but there is limited prospective data concerning the impact of race on antipsychotic metabolic outcomes among patients with schizophrenia... - Treating the mind and body in schizophrenia: risks and preventionJonathan M Meyer
San Diego VA Medical Center, La Jolla, CA 92161, USA
CNS Spectr 9:25-33. 2004.... - Bone mineral density in male schizophrenia patients: a reviewJonathan M Meyer
Departments of Psychiatry, University of California, San Diego, USA
Ann Clin Psychiatry 18:43-8. 2006.... - The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes
Department of Psychiatry, Yale School of Medicine, 300 George Street, Ste 901, New Haven, CT 06511, USA
Schizophr Res 128:166-70. 2011..Weight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit... - Antipsychotic prescribing practices following withdrawal of concomitant carbamazepineDanielle K Strack
Sharp Mesa Vista Hospital, San Diego, CA 92123, USA
J Psychiatr Pract 15:442-8. 2009.... - Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patientsHua Jin
Department of Psychiatry, University of California, San Diego, Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive MC 116A, San Diego, CA 92161, USA
J Clin Psychiatry 71:1273-8. 2010..However, there are relatively few data from antipsychotic-treated patients, especially on the association between these markers and the clinical MetS diagnosis... - Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapineJohn W Newcomer
Department of Psychiatry, and Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
Schizophr Res 106:300-7. 2008..This post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia... - Is there a therapeutic window with some antidepressants for analgesic response?J Hampton Atkinson
VA San Diego Healthcare System, 3350 La Jolla Village Drive, 116A, San Diego, CA 92161, USA
Curr Pain Headache Rep 13:93-9. 2009..This article reviews the strengths, limitations, and potential of therapeutic drug monitoring of antidepressants and anticonvulsants as analgesics for selected chronic pain syndromes... - Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric settingRyan J Kimmel
Department of Psychiatry, University of California San Diego, La Jolla, California 92093 0603R, USA
Int Clin Psychopharmacol 20:57-8. 2005..This case illustrates the need to check ammonia levels in psychiatric patients who are taking valproic acid and who present with new neurological symptoms... - A comprehensive review of behavioral interventions for weight management in schizophreniaCatherine Loh
Mental Illness Research, Education, and Clinical Centers MIRECC, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
Ann Clin Psychiatry 18:23-31. 2006..This review seeks to assess the potential of behavioral therapy for the management of obesity in individuals diagnosed with schizophrenia through a comprehensive review of all available literature on this subject... - Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinHua Jin
Department of Psychiatry, University of California at San Diego, USA
Schizophr Res 100:70-85. 2008..The purpose of this review is to summarize recent data on changes in these hormones during atypical antipsychotic treatment... - Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veteransAdrian W Dollarhide
VA San Diego Healthcare System, San Diego, CA 92161, USA
J Clin Gastroenterol 41:322-8. 2007..The aim of this study was to evaluate the impact of common psychiatric disorders on treatment completion of antiviral therapy prescribed to a series of hepatitis C virus (HCV) positive US veterans... - The metabolic syndrome and schizophrenia: a reviewJonathan Meyer
University of California-San Diego, San Diego, CA, USA
Int Rev Psychiatry 17:173-80. 2005..This article describes and summarizes the information available on metabolic syndrome in the mental illness disease area and the proposed mechanisms for the increased prevalence of the metabolic syndrome in this population... - Cardiovascular effects of antipsychoticsJames W Michelsen
University of California, San Diego, Department of Medicine, CA, USA
Expert Rev Neurother 7:829-39. 2007.... - Atypical antipsychotics and glucose dysregulation: a systematic reviewHua Jin
Department of Psychiatry, University of California, San Diego VAMC, 3350 La Jolla Village Drive MC 116A, San Diego, CA 92161, USA
Schizophr Res 71:195-212. 2004..Rational patient monitoring guidelines are also elucidated, particularly for high-risk populations that need more intensive scrutiny during treatment of AAP... - Sexual dysfunction in patients treated with atypical antipsychoticsJonathan M Meyer
Department of Psychiatry, University of California, San Diego, San Diego VAMC, USA
J Clin Psychiatry 69:e26. 2008..To establish clinically useful standards for switching agents, more studies are needed that focus on gradual cross-titration methods to achieve therapeutic doses for patients... - Drug-drug interactions with antipsychoticsJonathan Meyer
University of California, San Diego, USA
CNS Spectr 12:6-9. 2007 - Risperidone-induced retrograde ejaculation: case report and review of the literatureCatherine Loh
Mental Illness Research Education and Clinical Centers (MIRECC, Veterans Affairs San Diego Healthcare System, San Diego, California, USA
Int Clin Psychopharmacol 19:111-2. 2004..This case illustrates another mechanism for sexual adverse effects, and the need for routine inquiry into sexual dysfunction during atypical antipsychotic therapy... - Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published casesHua Jin
Department of Psychiatry, University of California at San Diego, USA
Ann Clin Psychiatry 14:59-64. 2002..Clinicians should be aware of the potential risks of new-onset DM and DKA in patients taking atypical antipsychotics, and utilize appropriate clinical and laboratory monitoring to prevent serious adverse events... - Evidence-based psychiatry: outcomes and decisionsJonathan M Meyer
South Med J 100:861-2. 2007 - A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsDonald C Goff
Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
Schizophr Res 80:45-53. 2005..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics... - Decreased bone mineral density in male schizophrenia patientsDavid Lehman
Schizophr Res 76:131-3. 2005 - Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baselineHenry A Nasrallah
University of Cincinnati, Cincinnati, OH 45267 0559, USA
Schizophr Res 86:15-22. 2006.... - Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIIJoseph P McEvoy
Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
Schizophr Res 80:19-32. 2005..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia... - Atypical antipsychotic therapy and hyperlipidemia: a reviewCarol E Koro
GlaxoSmithKline, Upper Providence, Pennsylvania, USA
Essent Psychopharmacol 6:148-57. 2005..Patients with persistent dyslipidemia should be referred for lipid-lowering therapy or switched to a less lipid-enhancing antipsychotic agent...
Research Grants
- The Metabolic Syndrome in Patients with SchizophreniaJonathan Meyer; Fiscal Year: 2007..abstract_text> ..